Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 149 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2014', provides an overview of the Cutaneous T-Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cutaneous T-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cutaneous T-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cutaneous T-Cell Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Cutaneous T-Cell Lymphoma - Overview 10
Pipeline Products for Cutaneous T-Cell Lymphoma - Comparative Analysis 11
Cutaneous T-Cell Lymphoma - Therapeutics under Development by Companies 12
Cutaneous T-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 14
Cutaneous T-Cell Lymphoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Cutaneous T-Cell Lymphoma - Products under Development by Companies 18
Cutaneous T-Cell Lymphoma - Products under Investigation by Universities/Institutes 19
Cutaneous T-Cell Lymphoma - Companies Involved in Therapeutics Development 20
Affimed Therapeutics AG 20
Chipscreen Biosciences Ltd 21
Cornerstone Pharmaceuticals, Inc. 22
Cyclacel Pharmaceuticals, Inc. 23
Eisai Co., Ltd. 24
Galderma S.A. 25
Innate Pharma SA 26
Johnson & Johnson 27
Kyowa Hakko Kirin Co., Ltd. 28
MedImmune, LLC 29
Neumedicines Inc. 30
Novartis AG 31
OncoSec Medical Inc. 32
Onyx Pharmaceuticals, Inc. 33
Seattle Genetics, Inc. 34
Soligenix, Inc. 35
TetraLogic Pharmaceuticals 36
Cutaneous T-Cell Lymphoma - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
A-dmDT390-bisFv - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AFM-13 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AMP-224 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Angeloxin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
bexarotene - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
brentuximab vedotin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
carfilzomib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CPI-613 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Dendritic Cell Therapy for Immunology and Oncology - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DNA IL-12 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
everolimus - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
HBI-8000 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
IPH-4102 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
mogamulizumab - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
NMIL-121 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
panobinostat - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
quisinostat - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Recombinant Protein for CNS, Oncology, Hematological Disorders and Metabolic Disorders - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
sapacitabine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SGX-301 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SHP-141 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
trifarotene - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Cutaneous T-Cell Lymphoma - Recent Pipeline Updates 95
Cutaneous T-Cell Lymphoma - Dormant Projects 139
Cutaneous T-Cell Lymphoma - Discontinued Products 141
Cutaneous T-Cell Lymphoma - Product Development Milestones 142
Featured News & Press Releases 142
Sep 17, 2014: Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 142
Aug 27, 2014: Innate Pharma's IPH4102 Receives Orphan Drug Designation In European Union 142
Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence 143
Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 144
Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma 144
Oct 08, 2013: OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study 144
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 145
Mar 04, 2013: Shape Pharma Provides Update On SHP-141 Topical HDAC Inhibitor Clinical Development For Cutaneous T Cell Lymphoma 146
Dec 13, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase III Trial Of Mogamulizumab In Patients With Cutaneous T-Cell Lymphoma In US 146
Dec 11, 2012: Kyowa Hakko Kirin Announces Presentation Of Phase II Clinical Trial Results Of Mogamulizumab At ASH Annual Meeting 147
Appendix 148
Methodology 148
Coverage 148
Secondary Research 148
Primary Research 148
Expert Panel Validation 148
Contact Us 149
Disclaimer 149

List of Tables
Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2014 10
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Cutaneous T-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2014 20
Cutaneous T-Cell Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2014 21
Cutaneous T-Cell Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2014 22
Cutaneous T-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 23
Cutaneous T-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2014 24
Cutaneous T-Cell Lymphoma - Pipeline by Galderma S.A., H2 2014 25
Cutaneous T-Cell Lymphoma - Pipeline by Innate Pharma SA, H2 2014 26
Cutaneous T-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2014 27
Cutaneous T-Cell Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 28
Cutaneous T-Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2014 29
Cutaneous T-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2014 30
Cutaneous T-Cell Lymphoma - Pipeline by Novartis AG, H2 2014 31
Cutaneous T-Cell Lymphoma - Pipeline by OncoSec Medical Inc., H2 2014 32
Cutaneous T-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 33
Cutaneous T-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014 34
Cutaneous T-Cell Lymphoma - Pipeline by Soligenix, Inc., H2 2014 35
Cutaneous T-Cell Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Mechanism of Action, H2 2014 41
Number of Products by Stage and Route of Administration, H2 2014 43
Number of Products by Stage and Molecule Type, H2 2014 45
Cutaneous T-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 95
Cutaneous T-Cell Lymphoma - Dormant Projects, H2 2014 139
Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..1), H2 2014 140
Cutaneous T-Cell Lymphoma - Discontinued Products, H2 2014 141